Cargando…
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-deve...
Autores principales: | Kunos, Charles A., Capala, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600139/ https://www.ncbi.nlm.nih.gov/pubmed/33008086 http://dx.doi.org/10.3390/ph13100287 |
Ejemplares similares
-
Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019) -
Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019) -
Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer
por: Kunos, Charles A., et al.
Publicado: (2020) -
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
por: Kunos, Charles A., et al.
Publicado: (2019) -
Phase 0 Radiopharmaceutical–Agent Clinical Development
por: Kunos, Charles A., et al.
Publicado: (2020)